# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Citigroup analyst Patrick Donnelly maintains Bruker (NASDAQ:BRKR) with a Buy and lowers the price target from $95 to $80.
Goldman Sachs analyst Matthew Sykes maintains Bruker (NASDAQ:BRKR) with a Sell and lowers the price target from $72 to $60.
Based on cellular biophysical markers attained using Bruker's advanced atomic force microscopy, Cellens is developing its p...
At the 72nd ASMS meeting, Bruker Corporation (NASDAQ:BRKR) announced the launch of a novel, high-performance MALDI-TOF/TOF syst...
Bruker shares are trading lower by 6.6% during Thursday's session. The company announced a public offering of 6 million sha...
Bruker intends to use the net proceeds from the offering to reduce indebtedness following its recent strategic acquisitions, in...
Bruker Corporation ("Bruker" or the "Company") (NASDAQ:BRKR) today announced the launch of an underwritten regi...